• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    10/16/24 9:01:20 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TNXP alert in real time by email
    SC 13G/A 1 p24-2970sc13ga.htm TONIX PHARMACEUTICALS HOLDING CORP.
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No. 1)*
     

    Tonix Pharmaceuticals Holding Corp.

    (Name of Issuer)
     

    Common Stock, $0.001 par value

    (Title of Class of Securities)
     

    890260847

    (CUSIP Number)
     

    September 30, 2024

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 9 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     CUSIP No. 890260847 13G-APage 2 of 9 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Empery Asset Management, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)¨

    (b)¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,739,864 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,739,864 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,739,864 shares of Common Stock issuable upon exercise of Warrants

    (See Item 4)

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.34% (See Item 4)

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

     CUSIP No. 890260847 13G-APage 3 of 9 Pages

     

     

    1

    NAMES OF REPORTING PERSONS

    Ryan M. Lane

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)¨

    (b)¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,739,864 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,739,864 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,739,864 shares of Common Stock issuable upon exercise of Warrants

    (See Item 4)

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.34% (See Item 4)

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     CUSIP No. 890260847 13G-APage 4 of 9 Pages

     

     

    1

    NAMES OF REPORTING PERSONS

    Martin D. Hoe

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)¨

    (b)¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    1,739,864 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    1,739,864 shares of Common Stock issuable upon exercise of Warrants (See Item 4)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,739,864 shares of Common Stock issuable upon exercise of Warrants

    (See Item 4)

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

    ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    1.34% (See Item 4)

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

     CUSIP No. 890260847 13G-APage 5 of 9 Pages

     

    Item 1(a). NAME OF ISSUER:
       
      The name of the issuer is Tonix Pharmaceuticals Holding Corp. (the “Company”).
    Item 1(b). ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:
       
      The Company’s principal executive offices are located at 26 Main Street, Suite 101, Chatham, NJ 07928.
    Item 2(a). NAME OF PERSON FILING:

     

      This statement is filed by the entities and persons listed below, who are collectively referred to herein as “Reporting Persons,” with respect to the Common Stock (as defined in Item 2(d) below) of the Company:
       
      Investment Manager
       
      (i) Empery Asset Management, LP (the “Investment Manager”), with respect to the shares of Common Stock held by, and underlying the Reported Warrants (as defined below) held by, funds to which the Investment Manager serves as investment manager (the “Empery Funds”).
       
      Reporting Individuals
       
      (ii) Mr. Ryan M. Lane (“Mr. Lane”), with respect to the shares of Common Stock held by, and underlying the Reported Warrants held by, the Empery Funds.
       
      (iii) Mr. Martin D. Hoe (“Mr. Hoe”), with respect to the shares of Common Stock held by, and underlying the Reported Warrants held by, the Empery Funds.
       
      The Investment Manager serves as the investment manager to each of the Empery Funds. Each of Mr. Lane and Mr. Hoe (the “Reporting Individuals”) is a Managing Member of Empery AM GP, LLC (the “General Partner”), the general partner of the Investment Manager.

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

      The address of the business office of each of the Reporting Persons is:
       
     

    1 Rockefeller Plaza, Suite 1205

    New York, New York 10020

     

    Item 2(c). CITIZENSHIP:

     

      Citizenship is set forth in Row 4 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.

     

     CUSIP No. 890260847 13G-APage 6 of 9 Pages

      

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common Stock, $0.001 par value (the “Common Stock”)

     

    Item 2(e). CUSIP NUMBER:
       
      890260847

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act,
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act,
      (c) ¨ Insurance Company as defined in Section 3(a)(19) of the Act,
      (d) ¨ Investment Company registered under Section 8 of the Investment Company Act of 1940,
      (e) x Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940,
      (f) ¨ Employee Benefit Plan or Endowment Fund in accordance with Rule 13d-1(b)(1)(ii)(F),
      (g) ¨ Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G),
      (h) ¨ Savings Association as defined in Section 3(b) of the Federal Deposit Insurance Act,
      (i) ¨ Church Plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940,
      (j) ¨ A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution:______________________________________

     

     CUSIP No. 890260847 13G-APage 7 of 9 Pages

      

    Item 4. OWNERSHIP.

     

      The information as of the date of the event which requires filing of this statement required by Items 4(a) – (c) is set forth in Rows 5 – 11 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person.  The percentage set forth in Row 11 of the cover page for each Reporting Person is based on 127,874,517 shares of Common Stock issued and outstanding as of September 12, 2024, as represented in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on September 23, 2024 and assumes the exercise of the Company’s reported warrants (the “Reported Warrants”).

     

      The Investment Manager, which serves as the investment manager to the Empery Funds, may be deemed to be the beneficial owner of all shares of Common Stock held by, and underlying the Reported Warrants held by, the Empery Funds.  Each of the Reporting Individuals, as Managing Members of the General Partner of the Investment Manager with the power to exercise investment discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by, and underlying the Reported Warrants held by, the Empery Funds.  The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of shares of Common Stock owned by another Reporting Person.  Each of the Empery Funds and the Reporting Individuals hereby disclaims any beneficial ownership of any such shares of Common Stock.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [X]

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
      Not applicable.

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
      Not applicable.

     

     CUSIP No. 890260847 13G-APage 8 of 9 Pages

     

     

    Item 10. CERTIFICATION.

     

      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     CUSIP No. 890260847 13G-APage 9 of 9 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: October 16, 2024

     

       
      EMPERY ASSET MANAGEMENT, LP
      By: EMPERY AM GP, LLC, its General Partner
       
      By:  /s/ Ryan M. Lane___________________
      Name:  Ryan M. Lane
      Title:  Managing Member
       
      /s/ Ryan M. Lane______________________
      Ryan M. Lane
       
      /s/ Martin D. Hoe______________________
      Martin D. Hoe

     

     

    Get the next $TNXP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TNXP

    DatePrice TargetRatingAnalyst
    4/18/2022Outperform
    Noble Capital Markets
    More analyst ratings

    $TNXP
    Leadership Updates

    Live Leadership Updates

    See more
    • Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights

      August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Company expects to have sufficient cash to fund planned operations beyond the FDA PDUFA goal date and anticipated fourth quarter 2025 launch of TNX-102 SL for fibromyalgia; $98.8 million in cash as of December 31, 2024 Announced positive topline results from Phase 1 study of TNX-1500, a next generation anti-CD40L mAb candidate for prevention of kidney transplant rejection and treatment of autoimmune diseases Received government grant for potential mpox vaccine, TNX-801, which has demonst

      3/18/25 4:30:00 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Gary Ainsworth as Vice President of Market Access

      Mr. Ainsworth brings over two decades of industry and market access experience to Tonix U.S. Food and Drug Administration (FDA) recently assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for U.S. marketing authorization of TNX-102 SL for the management of fibromyalgia CHATHAM, N.J., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the appointment of Gary Ainsworth as Vice President, Market Access, effective immediately. Mr. Ainsworth is an accomplished executive with leadershi

      1/8/25 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires

      Tonix appoints two executives with decades of experience successfully launching and commercializing new CNS products Bradley Raudabaugh, MBA, joins as Vice President, Marketing, bringing over 25 years of marketing, sales and product planning experience to Tonix Errol Gould, Ph.D., joins Tonix as Vice President, Medical Affairs, with over 25 years of experience in R&D and medical affairs across a wide range of therapeutic areas, including fibromyalgia New Drug Application (NDA) for TNX-102 SL for the management of fibromyalgia submitted to FDA in October 2024; NDA acceptance expected December 2024; Fast Track designation previously granted by FDA; FDA decision on approval expected 2025 If

      12/3/24 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting

      Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cells TNX-1700 is in preclinical development for gastric and colorectal cancers CHATHAM, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, presented data in a poster presentation at the American Association for Cancer Research (AACR) 2025 Annual Meeting, held April 25-30, 2025, in Chicago, IL. A copy of the Company's presentation is available under the Scient

      4/29/25 9:05:04 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

      TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised animals from a lethal challenge with clade IIa monkeypox virus Durability of TNX-801 vaccination shown by six-month protection of animals from a lethal challenge with rabbitpox Tolerability of TNX-801 demonstrated in immunocompromised animals by no spreading to blood or tissues, even at high doses CHATHAM, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, presented data in an

      4/24/25 7:55:30 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025

      CHATHAM, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the Company will deliver an oral presentation and lead a panel discussion at the World Vaccine Congress Washington 2025, which will be held in Washington, D.C., April 22-24, 2025. A copy of the Company's presentation will be available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com following the conference. Additional meeting information can be found on the World Vaccine Congress website here. Presentati

      4/16/25 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bell Margaret Smith disposed of $0 worth of shares (1 units at $0.15), closing all direct ownership in the company (SEC Form 4)

      4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

      2/28/25 5:32:22 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Treco James disposed of $0 worth of shares (0 units at $0.30), closing all direct ownership in the company (SEC Form 4)

      4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

      2/28/25 5:31:48 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Olukotun Adeoye Y disposed of $2 worth of shares (1 units at $1.91), closing all direct ownership in the company (SEC Form 4)

      4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

      2/28/25 5:31:25 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Noble Capital Markets initiated coverage on Tonix Pharma

      Noble Capital Markets initiated coverage of Tonix Pharma with a rating of Outperform

      4/18/22 9:20:45 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alliance Global Partners resumed coverage on Tonix Pharmaceuticals with a new price target

      Alliance Global Partners resumed coverage of Tonix Pharmaceuticals with a rating of Buy and set a new price target of $4.00 from $3.00 previously

      2/25/21 7:39:46 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

      SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

      11/14/24 4:42:22 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

      SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

      11/14/24 4:40:17 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

      SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

      10/16/24 9:01:20 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    Financials

    Live finance-specific insights

    See more
    • Tonix Pharmaceuticals Completes Acquisition of Two FDA-Approved, Marketed Migraine Products

      Strategic Acquisition Helps Build Tonix's Commercial Capabilities and Infrastructure Ahead of Potential Launch of TNX-102 SL for the Management of Fibromyalgia Acquisition of Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray), Indicated for the Treatment of Acute Migraine in Adults, Complements Tonix's Current Intranasal Clinical Development Program of TNX-1900 for Migraine Prevention CHATHAM, N.J., July 03, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix Pharmaceuticals or Tonix), a biopharmaceutical company, and its wholly-owned commercialization subsidiary Tonix Medicines, Inc. (Tonix Medicines), today announced it

      7/3/23 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights

      Five Potentially Pivotal Phase 2 or 3 Studies for CNS Programs Expected to be in the Clinic by First Quarter 2023 Data from Planned Interim Analyses of TNX-102 SL in Phase 3 Fibromyalgia Study and Phase 2 Long COVID Study Expected Second Quarter 2023 Advanced Development Center in Dartmouth, Mass. and Infectious Disease Research and Development Facility in Frederick, Md. Operational Cash and Cash Equivalents Totaled Approximately $140 Million at September 30, 2022 CHATHAM, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced financial results for the

      11/7/22 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Advanced Development Center (ADC) for Vaccine Programs in Massachusetts

      The ADC is Expected to Accelerate Clinical-Scale Manufacturing of Live Virus Vaccines, Including Vaccines for Monkeypox, Smallpox and COVID-19 Internal Manufacturing Capabilities Expected to Support U.S. Pandemic Preparedness CHATHAM, N.J., June 16, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced it will hold a ribbon-cutting ceremony at the Company's 45,000 square foot clinical-scale manufacturing facility in the New Bedford Business Park in North Dartmouth, Massachusetts on June 21, 2022 at 1:00 pm ET. The new facility houses Tonix's Advanced Development Center (ADC) for acce

      6/16/22 7:00:00 AM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TNXP
    SEC Filings

    See more
    • SEC Form 8-K filed by Tonix Pharmaceuticals Holding Corp.

      8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

      5/8/25 5:16:06 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

      4/29/25 4:08:13 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events

      8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

      4/25/25 4:59:30 PM ET
      $TNXP
      Biotechnology: Pharmaceutical Preparations
      Health Care